# Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

> **NCT05145400** · PHASE2 · RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma
- Cancer

## Interventions

- **DRUG:** Isatuximab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05145400
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-18
- **Primary completion:** 2026-03-01
- **Final completion:** 2031-03-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05145400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05145400, "Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05145400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*